The Nonselective ?-Blocker Carvedilol Suppresses Apoptosis in Human Cardiac Tissue: A Pilot Study

Authors

  • Engin Usta
  • Migdat Mustafi
  • Andreas Straub
  • Gerhard Ziemer

DOI:

https://doi.org/10.1532/HSF98.20091179

Abstract

Background: Cardioplegia and reperfusion of the myocardium may be associated with cardiomyocyte apoptosis and subsequent myocardial injury. To establish a pharmacologic strategy for the prevention of these events, this study aimed to verify the reliability of our human cardiac model and to evaluate the antiapoptotic properties of the nonselective ?-blocker carvedilol during simulated cardioplegia and reperfusion ex vivo.

Methods: Cardiac biopsies were retrieved before induction of cardiopulmonary bypass from the auricle of the right atrium of patients undergoing elective coronary artery bypass grafting. Biopsies were exposed to ex vivo conditions of varying periods of cardioplegia/reperfusion (30/10 minutes, 60/20 minutes, 120/40 minutes). Group I was the untreated control (n = 15), group II was the treated control (cardioplegia/reperfusion, n = 15), and group III was the experimental group (cardioplegia/reperfusion plus carvedilol, n = 15). Immunostaining for antibodies to activated caspase 3 and poly(ADP-ribose) polymerase 1 (PARP-1) cleavage was used to detect apoptosis.

Results: The percentage of apoptotic cardiomyocytes was significantly lower (P < .05) in group I than in group II, revealing a time-dependent increase. In group III, carvedilol treatment suppressed apoptosis significantly (P < .05).

Conclusion: Carvedilol significantly suppresses apoptosis in our ex vivo setting. This finding warrants further studies to evaluate the potential beneficial effects of carvedilol in suppressing ischemia/reperfusion injury in clinical settings.

References

Ak K, Akgun S, Tecimer T, et al. 2005. Determination of histopathologic risk factors for postoperative atrial fibrillation in cardiac surgery. Ann Thorac Surg 79:1970-5.nAmos GJ, Wettwer E, Metzger F, Li Q, Himmel HM, Ravens U. 1996. Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol 491:31-50.nBai CX, Namekata I, Kurokawa J, Tanaka H, Shigenobu K, Furukawa T. 2005. Role of nitric oxide in Ca2+ sensitivity of the slowly activating delayed rectifier K+ current in cardiac myocytes. Circ Res 96:64-72.nCommunal C, Sumandea M, de Tombe P, Narula J, Solaro RJ, Hajjar RJ. 2002. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci U S A 99:6252-6.nDanial NN, Korsmeyer SJ. 2004. Cell death: critical control points. Cell 116:205-19.nGroholm T, Finckenberg P, Palojoki E, et al. 2004. Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet. Hypertens Res 27:609-18.nKaiser RA, Bueno OF, Lips DJ, et al. 2004. Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem 279:15524-30.nKawai K, Qin F, Shite J, Mao W, Fukuoka S, Liang CS. 2004. Importance of antioxidant and antiapoptotic effects of beta-receptor blockers in heart failure therapy. Am J Physiol Heart Circ Physiol 287:H1003-12.nKhoynezhad A, Jalali Z, Tortolani AJ. 2007. A synopsis of research in cardiac apoptosis and its application to congestive heart failure. Tex Heart Inst J 34:352-9.nKubasiak LA, Hernandez OM, Bishopric NH, Webster KA. 2002. Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci U S A 99:12825-30.nLotze U, Heinke S, Fritzenwanger M, Krack A, Müller S, Figulla HR. 2002. Carvedilol inhibits platelet-derived growth factor-induced signal transduction in human cardiac fibroblasts. J Cardiovasc Pharmacol 39:576-89.nMiyamoto S, Howes AL, Adams JW, Dorn GW 2nd, Brown JH. 2005. Ca2+ dysregulation induces mitochondrial depolarization and apoptosis: role of Na+/Ca2+ exchanger and AKT. J Biol Chem 280:38505-12.nMurriel CL, Churchill E, Inagaki K, Szweda LI, Mochly-Rosen D. 2004. Protein kinase C activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria. J Biol Chem 279:47985-91.nRao RV, Hermel E, Castro-Obregon S, et al. 2001. Coupling endoplasmic reticulum stress to the cell death program. Mechanism of caspase activation. J Biol Chem 276:33869-74.nRen J, Wold LE, Natavio M, Ren BH, Hannigan JH, Brown RA. 2002. Influence of prenatal alcohol exposure on myocardial contractile function in adult rat hearts: role of intracellular calcium and apoptosis. Alcohol Alcohol 37:30-7.nTewari M, Quan LT, O'Rourke K, et al. 1995. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81:801-9.nWang R, Miura T, Harada N, et al. 2006. Pleiotropic effects of the beta-adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes. J Pharmacol Exp Ther 318:45-52.nWeinlich M, Baumstark C, Usta E, Becker HD, Sessler MJ. 2002. Human duodenal spheroids for noninvasive intracellular pH measurement and quantification of regulation mechanisms under physiological conditions. In Vitro Cell Dev Biol Anim 38:7-13.nZaugg M, Xu W, Lucchinetti E, Shafiq SA, Jamali NZ, Siddiqui MA. 2000. Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes. Circulation 102:344-50.nZhang S, Sun Z, Liu L, Hasichaonu. 2003. Carvedilol attenuates CPB-induced apoptosis in dog heart: regulation of Fas/FasL and caspase-3 pathway. Chin Med J (Engl) 116:761-6.n

Published

2010-08-18

How to Cite

Usta, E., Mustafi, M., Straub, A., & Ziemer, G. (2010). The Nonselective ?-Blocker Carvedilol Suppresses Apoptosis in Human Cardiac Tissue: A Pilot Study. The Heart Surgery Forum, 13(4), E218-E222. https://doi.org/10.1532/HSF98.20091179

Issue

Section

Articles